

## HCA Midwest Health joins SAPPHIRE Study

Strengthens U.S. footprint of Artrya's SAPPHIRE Study ahead of 2026 launch

**PERTH, Australia, 29 January 2026:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix<sup>®</sup> AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that HCA Midwest Health has agreed to in-principle participation in the retrospective U.S. multi-centre SAPPHIRE Study, pending protocol and ethics review.

**John Konstantopoulos, Co-Founder and CEO of Artrya commented:**

*"We are very pleased to have Dr Bloom and HCA Midwest join our upcoming SAPPHIRE Study which is now close to launch. They have a strong cardiology practice in Kansas City which also broadens the geographic spread of the SAPPHIRE Study."*

**Stephen Bloom, MD, MSCCT, FASNC, FAHA, FACP, FACC, Director of Advanced Imaging at Midwest Heart and Vascular Specialists commented:**

*"We are excited about the SAPPHIRE Study as we see a major need for coronary CT with plaque analysis using AI technology to allow us to diagnose coronary artery disease in the early stages before having chest pain or a heart attack. We can reduce heart disease with this technology and finally reduce the number 1 killer in the world"*

## SAPPHIRE Study expands with HCA Midwest Health

HCA Midwest Health's inclusion brings another distinguished, high-volume U.S. cardiology centre into the upcoming SAPPHIRE Study, set to launch in early 2026. The Salix<sup>®</sup>-based Analysis of Plaque to Identify Patients at Higher Risk of Events (**SAPPHIRE**) Study is a multi-centre, real-world study evaluating the prognostic and clinical utility of Artrya's Salix<sup>®</sup> Plaque Analysis and the Plaque Dispersion Score (**PDS**). These AI-powered tools aim to identify high-risk coronary artery disease patients with greater precision than traditional risk models. A more accurate assessment requires the analysis of individual plaque features, which is impractical for human readers of CCTA scans, but can be enabled using AI platforms.

Dr Bloom is a board-certified, fellowship-trained invasive cardiologist with Midwest Heart and Vascular Specialists in Overland Park, KS. Dr. Bloom has practiced cardiology for more than 30 years and is board certified in four specialties: internal medicine, cardiovascular disease, nuclear cardiology, and cardiovascular computed tomography.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](http://www.linkedin.com/company/artrya)

## Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

## For more information:

### Corporate Enquiries

#### John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

### Investor & Media Enquiries

#### David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)